Sanofi lining up billions for a major buyout

With virtually every Big Pharma company looking to make a major acquisition, the Financial Times reports that Sanofi-Aventis is in talks with bankers to line up enough money for new acquisitions. And analysts weren't shy about identifying potential takeover targets. At the top of the list: Amgen, Biogen Idec and Bristol-Myers Squibb.

Lack of money won't be an issue. UBS is estimating that Sanofi-Aventis could raise anywhere from $22 billion to $26 billion. Crucell, the last big independent vaccine maker, is also on the target list. And Sanofi could opt to invest heavily in generics.

All of that is a roundabout way of saying that just about anything is possible. But with Pfizer buying Wyeth, Roche intent to capture Genentech and a string of other pharma companies already digesting big acquisitions, remaining on the sidelines evidently is no longer an option for Sanofi.

- check out the report from the Financial Times 

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.